GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Net Income Including Noncontrolling Interests

Innate Pharma (XPAR:IPH) Net Income Including Noncontrolling Interests : €-34.05 Mil (TTM As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Innate Pharma's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2024 was €-24.76 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 was €-34.05 Mil.

Innate Pharma Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Innate Pharma's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Net Income Including Noncontrolling Interests Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.76 -63.98 -52.81 -58.10 -7.57

Innate Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.30 -64.41 1.72 -9.29 -24.76

Innate Pharma Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-34.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XPAR:ADOC XPAR:IVA XPAR:MAAT XPAR:TNG XPAR:NANO XPAR:ALCLS XPAR:ALSEN XPAR:OSE XPAR:DBV XPAR:GNFT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany IDD:Germany IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines